---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-26-000045"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2026-08-06T20:32:07+00:00"
generated_at: "2026-08-06T20:33:17.793293+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91

## Summary
- Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.
- GAAP net income $30.3M ($0.67 diluted EPS) vs $31.0M ($0.64) year ago.
- Adjusted non-GAAP net income $40.8M ($0.91 diluted EPS) vs $40.9M ($0.85).
- CEO cites revenue growth, gross margin expansion, new product launches, and pipeline progress.
- Six-month 2026 GAAP net income $36.8M ($0.81) vs $56.3M ($1.15) in prior year.

## SEC filing metadata
- accession: 0001297184-26-000045
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2026-08-06T20:32:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/0001297184-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-26-000045
- JSON: https://secwatch.observer/filing/0001297184-26-000045.json
- Plain text: https://secwatch.observer/filing/0001297184-26-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.